Flexion Therapeutics Inc. (FLXN) Director Samuel D. Colella Buys 33,333 Shares
Flexion Therapeutics Inc. (NASDAQ:FLXN) Director Samuel D. Colella acquired 33,333 shares of the business’s stock in a transaction on Monday, November 21st. The shares were purchased at an average price of $18.00 per share, with a total value of $599,994.00. Following the transaction, the director now owns 25,504 shares in the company, valued at approximately $459,072. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Flexion Therapeutics Inc. (NASDAQ:FLXN) traded up 3.05% during midday trading on Wednesday, hitting $18.56. 147,223 shares of the company’s stock traded hands. The company’s market capitalization is $510.90 million. Flexion Therapeutics Inc. has a 52 week low of $7.56 and a 52 week high of $23.57. The company has a 50 day moving average of $19.37 and a 200-day moving average of $16.56.
Flexion Therapeutics (NASDAQ:FLXN) last issued its quarterly earnings data on Monday, November 7th. The specialty pharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.02. Equities research analysts predict that Flexion Therapeutics Inc. will post ($2.76) earnings per share for the current year.
Several large investors have recently modified their holdings of FLXN. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Flexion Therapeutics by 27.4% in the second quarter. Gilder Gagnon Howe & Co. LLC now owns 4,307,870 shares of the specialty pharmaceutical company’s stock valued at $64,467,000 after buying an additional 927,625 shares during the period. Peregrine Capital Management LLC acquired a new stake in shares of Flexion Therapeutics during the third quarter valued at approximately $14,126,000. TPG Group Holdings SBS Advisors Inc. acquired a new stake in shares of Flexion Therapeutics during the second quarter valued at approximately $10,689,000. Bank of New York Mellon Corp boosted its stake in shares of Flexion Therapeutics by 64.3% in the second quarter. Bank of New York Mellon Corp now owns 1,594,026 shares of the specialty pharmaceutical company’s stock valued at $23,855,000 after buying an additional 623,763 shares during the period. Finally, BlackRock Fund Advisors boosted its stake in shares of Flexion Therapeutics by 33.5% in the third quarter. BlackRock Fund Advisors now owns 1,003,825 shares of the specialty pharmaceutical company’s stock valued at $19,615,000 after buying an additional 251,804 shares during the period. Institutional investors and hedge funds own 68.99% of the company’s stock.
A number of equities analysts have commented on FLXN shares. Lake Street Capital restated a “buy” rating and set a $38.00 price objective on shares of Flexion Therapeutics in a research report on Tuesday, September 6th. Zacks Investment Research downgraded shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, September 8th. Cantor Fitzgerald restated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a research report on Wednesday, November 2nd. Finally, BCS cut their price objective on shares of Flexion Therapeutics from $0.65 to $0.02 in a research report on Tuesday, November 8th. One equities research analyst has rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the stock. Flexion Therapeutics has a consensus rating of “Buy” and a consensus target price of $28.28.
About Flexion Therapeutics
Flexion Therapeutics, Inc is a specialty pharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis and post-operative pain. The Company’s portfolio of product candidates addresses the OA pain treatment spectrum, from moderate to severe pain.
Receive News & Stock Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related stocks with our FREE daily email newsletter.